Kornimate/medical-research-clean huggingface dataset:
evaluation of the effectiveness of bian-stone therapy in children with autism spectrum disorder

Conditions: Evaluation of Bian Stone Therapy for Autism Spectrum Disorder

Summary: autism spectrum disorder (asd) is a pervasive developmental disorder of brain abnormalities. it presents with difficulties of communication and social interaction, and restrictive interests and restrictive behaviors. the cdc suggested that the popularity of asd people is 1.5% in the us, and the male to female ratio is 4.5 to 1. in taiwan, the popularity is around 1%, with the number increasing in recent years. the exact etiology of asd has remained unknown. currently, the treatments include behavioral therapies, medication and alternative therapies. however, there is no specific way to cure the core symptoms of asd. this study plans to apply behavioral therapies and traditional chinese medical bian-stone therapies on asd children and compare the results between asd children with only behavioral therapies. we will record theautism behavior checklist-taiwan version, development screening chart for children aged 0-6 years, and vineland adaptive behavior scales, third edition (vineland-3) before and after the treatments, and meanwhile using the ryodoraku measurement (良導絡) to measure the meridian energy. this study aims to evaluate the effectiveness of traditional chinese medical bian-stone therapies in asd children. in addition, we hope to investigate the relationship between asd symptoms and twelve meridians and assess the patterns in chinese medicine. hopefully this study will help strengthen the clinical evidence in tcm treatments for asd children and improve the efficacy of this disease.


Eligibility criteria:
inclusion criteria: * 1.diagnosed with autism spectrum disorder (asd) based on dsm-5 diagnostic criteria, and additionally screened using the t-stat assessment tool, with severity categorized as mild or moderate. 2.patients aged between 1.5 and under 6 years, regardless of gender. 3.a full-scale iq of 70 or above as measured by the wechsler intelligence scale for children (wisc). 4.no prior experience with bianshi therapy. 5.consent obtained from the patient or their guardian to provide relevant clinical data for use in this study. exclusion criteria: * 1.individuals who do not meet the aforementioned inclusion criteria. 2.severe hearing, visual, or motor impairments, or diagnoses of cerebral palsy or epilepsy. 3.presence of other comorbid conditions, such as tuberous sclerosis, fragile x syndrome, timothy syndrome, male rett syndrome (with mecp2 gene mutation), and other chromosomal abnormalities (e.g., angelman syndrome, prader-willi syndrome, phelan-mcdermid syndrome, and other related syndromes). 4.use of dietary supplements or health products.

Keywords: bian-stone therapy
lidocaine analgesia for removal of wound vac dressings

Conditions: Pain

Summary: the purpose of this prospective study is to compare pain levels and pain medication dose requirements in patients with topical negative pressure (tnp) dressings removed in a standard manner (i.v. or p.o. pain meds) compared to dressings removed with lidocaine analgesia, via injection retrograde up the suction tube into the foam prior to removal. our null hypothesis is that there will be no difference in overall pain scores or medication requirements when patients receive a saline, control injection and pain medications, compared to when their dressings are changed with a lidocaine injection into the sponge, with pain medications. our objective is to disprove this null hypothesis with statistical significance.


Eligibility criteria:
inclusion criteria: 1. wounds to which a split-thickness autologous skin graft applied; 2. infected wounds after debridement; 3. open fracture wounds; 4. acute soft-tissue wounds (with exposed tendon, bone, hardware, and/or joint); 5. fasciotomy wounds after compartment syndrome; 6. chronic non-healing wounds; 7. surgical wounds that are difficult to close due to tension; or 8. wounds with external fixation pins or tubes with irritation or drainage. exclusion criteria: 1. allergy to lidocaine; 2. allergy to the polyurethane foam or impermeable seal; 3. malignancy associated with the wound; 4. extremity insensate to pain due to any cause (including diabetic neuropathy, or any neurologic disorder therein); 5. pregnancy as diagnosed by urine pregnancy test.

Keywords: wound vacuum assisted dressings lidocaine dressing change pain management palliative care
seal registry - european registry for the effectiveness of lifeseal® kit

Conditions: Anastomotic Leakage

Summary: this study will assess the effectiveness of commercially available lifeseal® kit as measured by the incidence of post-operative clinical anastomotic leak rates in subjects undergoing low and ultralow anterior resection with an anastomosis. all patients treated with lifeseal® will be offered to participate

the lifeseal® kit is a novel surgical sealant intended to be used as an adjunct to suture or staple line during standard surgical repair of the gi tract (anastomosis or linear) to provide re-inforcement and help reduce leaks. the lifeseal™ kit has recently been ce certified on march 2016 for marketing in the european union.

Eligibility criteria:
inclusion criteria: 1. ≥ 18 years of age at screening visit 2. written informed consent obtained 3. subject is scheduled to have or already underwent elective open, laparoscopic or robot assisted surgery involving the creation of a coloanal or colorectal anastomosis\* created within 15 cm from the anal verge. 4. subject was already treated or is scheduled to be treated with lifeseal® kit, applied according to the ifu exclusion criteria: 1. subject with american society of anesthesiology (asa) status \> 3.
does pre-injection local anesthesia affect experienced pain during intra-articular hip injections.

Conditions: Pain; Injection; Prevention; Assessment

Summary: intra-articular hip injections are commonly used for diagnostic and therapeutic purposes but are often associated with patient anxiety and fear. the disparity between anticipated and experienced pain during these injections, as well as the role of pre-injection local anesthesia in pain modulation, remains unclear. this study investigates the difference between anticipated and experienced pain during intra-articular hip injections. in addition, the study examines the impact of pre-injection local anesthesia in 60 prospectively recruited patients, some of whom received pre-injection local anesthesia while others did not. these study findings provide valuable insights into experienced pain during intra-articular hip injections, which can be applied to improve patient experiences and treatment compliance.

1. identification of patients in the outpatient clinic and completion of the questionnaires will be carried out by the principal investigator and sub-investigators in the clinic. 2. data processing will be conducted by physicians holding an md certification. 3. the type of study is prospective. 4. data collection will be performed using the medical records of tel aviv medical center hospital only, covering the years 2021 and 2022. 5. demographic data will be collected, including gender, year of birth, age, diagnosis, indication for injection, and previous treatments. clinical data will include underlying diseases, side of injection, complications, indications, and follow-up time.

Eligibility criteria:
inclusion criteria: * patients undergoing a first-time intra-articular hip injection as indicated by an orthopedic surgeon. * indications for injection include: * diagnostic purposes (e.g., lidocaine test, arthrography) * therapeutic purposes (e.g., steroid injection for osteoarthritis) * participants must be 18 years of age or older. * no previous hip joint injections. * ability to fill in the survey questionnaire. exclusion criteria: * patients under 18 years of age. * patients with a known history of hypersensitivity or allergy to the injectant material (e.g., local anesthetics, steroids). * patients lacking the ability to sign informed consent or complete a survey questionnaire. * patients with previous hip joint injections, due to the potential for recalling prior pain experienced.

Keywords: pain injection intra-articular expectation compliance
the role of epigenetic mechanisms in stress intolerance in patients with chronic widespread pain

Conditions: Chronic Widespread Pain

Summary: patients with chronic widespread pain (cwp) frequently experience stress intolerance - an exacerbation of symptoms in response to stress. although it severely affects their quality of life, stress intolerance remains a mystery. hence, unravelling the mechanisms underlying stress intolerance is crucial to understand cwp pathophysiology and to develop novel treatments. epigenetic mechanisms hold the potential to provide an answer as they have been found to be altered in patients with cwp at baseline, and in response to stress. however, research on epigenetic mechanisms in cwp is very scarce. hence, this study aims to address this knowledge gap by assessing stress-induced epigenetic changes in patients with cwp and healthy controls aiming to unravel whether epigenetic mechanisms can help explain stress intolerance. the regulatory role of epigenetic mechanisms will be researched in relation to the activity of enzymes affected by the epigenetic mechanisms, neurophysiological measures, and stress-induced symptom changes in patients with cwp.

the objectives of this project will be tackled by a randomized cross-over study including 44 patients with cwp and 44 healthy controls. participants are expected to come to the hospital twice and fill in questionnaires at several defined timepoints. two days before their first visit, participants will complete baseline questionnaires at home via redcap, which will take approximately one hour. next, participants will be randomised into group 1 (undergoing the mental stress test at their first visit and then relaxation breathing) or group 2 (undergoing relaxation breathing at their first visit and then the mental stress test). during each hospital visit, the participants will be assessed before, during and after the intervention. the pre-test assessment consists of a blood withdrawal, five short questionnaires, examination of pain thresholds, and neurophysiological measurements. the latter will continue during the intervention, which consists of a mental stress test or relaxation breathing. the post-test assessment consists of a blood withdrawal, one short questionnaire, examination of pain thresholds, and neurophysiological measurements. then there are again 2 home-based assessments via redcap 24h and 7 days after the intervention during which the participants will in 1 or 5 short questionnaires, respectively.

Eligibility criteria:
inclusion criteria: * female * age between 18 and 70 years old * body mass index (bmi) below 30 * inactive lifestyle * for patients only: received the diagnosis of fibromyalgia exclusion criteria: * other neurological, endocrine, cardiac, or systemic syndromes * history of cancer or heart failure * women that are pregnant or within one year after pregnancy

Keywords: chronic widespread pain epigenetics autonomic nervous system stress intolerance
pulsed electro-magnetic field therapy for treatment of midportion achilles tendinopathy

Conditions: Mid-portion Achilles Tendinopathy

Summary: this is a multi-centre, randomised, double-blind, placebo-controlled trial with two parallel groups in a 1:1 allocation to study the efficacy of pulsed electromagnetic field therapy (pemf) in patients with mid-portion achilles tendinopathy. all participants will be randomly divided into two groups: an intervention group (active pemf and standard rehabilitation exercise) and a control group (sham pemf and standard rehabilitation exercise). all self-reported, functional, and ultrasound findings will be evaluated by the investigator at baseline assessment, 1-month, 2-month, 3-month, 6-month and 12-month follow-up after initiating the intervention. the researcher will obtain written consent from all participants before the start of this study. all eligible participants will be informed about this study and given enough time to consider whether or not to participate; the clinician/research staff will answer all questions asked by the participants. the trial will be conducted in accordance with the declaration of helsinki and the ich-gcp. clinical research ethics approval for the trial will be obtained from the joint clinical research ethics committee of the chinese university of hong kong. all participants will be recruited from the clinics and centres of the participating institutions.


Eligibility criteria:
inclusion criteria: * adults (\>18 years of age) * clinical diagnosis of mid-achilles tendinopathy * visa-a score of \<60 * ultrasound evidence of achilles tendinopathy (thickening \>7mm) exclusion criteria: * previous invasive treatment to the achilles tendon (e.g. rupture repair, prp injection etc) * contraindication to pemf (e.g. pregnancy, pacemakers) * physical or psychological comorbidities impairing the ability to complete assessments (eg neurological deficits etc.)
the microbiome of infertile couples and its effect on their reproductive outcomes

Conditions: Abnormal Vaginal Microbiota; Infertility

Summary: a prospective cohort study in ivf patients at 5 ivf centres in denmark. the primary aim is to include patients positive for abnormal vaginal microbiota to an rct (eudract 2016-002385-31). secondary aims are the prevalence of abnormal vaginal microbiota in women undergoing ivf treatment, intimate hygiene and relations to the vaginal microbiota, basic fertility work up in relation to vaginal microbiota.

at the time of the interim stage of the rct (eudract 2016-002385-31), we plan to make a first cross-sectional investigation of the intimate hygiene questionnaire at baseline as compared to abnormal vaginal microbiota. we plan to make focused interview of n=30 patients to cover any additional female hygiene details not covered in the original questionnaire. after this investigation we may include new questions after the interim analysis - given that the study proceeds. in this case we plan to publish the first results of the intimate hygiene habits of the patients enrolled until interim stage.

Eligibility criteria:
inclusion criteria: * first, second or third ivf stimulation cycle at the involved clinic. * bmi\<35. * written informed consent. * 18-42 years old exclusion criteria: * hiv, hepatitis b or c positivity. * intrauterine malformations (vaginal ultrasound) * hysterosalpinx * known severe renal or hepatic impairment. * hpv cin 2 or higher. * patients treated with vitamin k antagonists (warfarin) * known or suspected hypersensitivity to clindamycin or any other antibiotic. * myastenia gravis * former or current inflammatory bowel disease, including mb. crohn and colitis ulcerosa * any uncontrolled concomitant disease (e.g. uncontrolled diabetes, uncontrolled hypertension etc.)
terlipressin administration in septic shock refractory to catecholamines

Conditions: Septic Shock

Summary: terlipressin is given to refractory septic shock patients who do not respond to noradrenalin in israel and europe. it is given by bolus injection. we attempt to investigate weather it is better to give it by continuous drip and avoid abrupt changes in bp and heart function


Eligibility criteria:
inclusion criteria: * septic shock patients receiving above 0.5 mcg/kg na exclusion criteria: * allergy to terlipressin, chf, ihd, pregnancy

Keywords: septic shock refractory to catecholamines
a 4 week study of elidel (pimecrolimus) for the treatment of seborrheic dermatitis

Conditions: Seborrheic Dermatitis

Summary: this is an exploratory study to determine effectiveness of elidel for the treatment of seborrheic dermatitis

this is a 4 week study for patients 18 and older to compare the efficacy and safety of pimecrolimus cream 1% twice daily and ketaconazole cream 2 % twice daily for the treatment of seborrheic dermatitis.

Eligibility criteria:
inclusion criteria: * must be 18 or older and sign written informed consent. * must be wiling and able to comply with protocol. * must have active seborrheic dermatitis of the face. exclusion criteria: * no history of overt bacterial, viral or fungal infection of the head/neck. * no history or presence of compromising dermatosis elsewhere on the skin * no parkinson's disease, hiv, infections or disorders of the central nervous system * no actinically damaged skin

Keywords: seborrheic dermatitis
cftr modulators and gastrointestinal complications

Conditions: Cystic Fibrosis; Gastrointestinal System Disease; Distal Intestinal Obstruction Syndrome; Pancreatic Enzyme Abnormality; Pancreatic Disease; Lung Diseases; Digestive System Disease

Summary: to elucidate the similarities and distinctions in non-pulmonary manifestations of cystic fibrosis (cf) including distal intestinal obstruction syndrome (dios) incidence and pancreatic enzyme replacement therapy (pert) use between us and uk cf populations in a parallel study using data from the uk and us cf registries. to assess how cftr modulators impacted upon recorded pert use and incidence of dios.

cystic fibrosis (cf) is a autosomal recessive multi-system disorder caused by mutations to the cystic fibrosis transmembrane conductance regulator (cftr) gene. as well as the documented respiratory complications of cf, gastrointestinal manifestations are of clinical importance. cftr mutations in the gastrointestinal tract are responsible for pancreatic exocrine insufficiency in around 85% of people with cf (pwcf). in addition a severe gastrointestinal complication in cf is distal intestinal obstructive syndrome (dios), affecting 5.7% pwcf in the uk (2.5% in \<16 years and 7.7% in adults) and 2.1% in the us (\<18 years 1.7%, adult 2.4%) in 2019. this is a parallel data registry study using data from the uk and us cf registries, with data provided for the time period 2007-2018. as such no individual participants will be recruited to the study. the cftr modulators to be studies are ivacaftor and lumacaftor/ivacaftor. study aims; * describe dios events and pert usage in uk and us registries * determine the effect of cftr modulators on the incidence of dios and use of pert: population time series * determine the effect of cftr modulators on the incidence of dios and use of pert: patient-level time series the outcomes of the above aims will be used to generate hypotheses regarding the effect of the newer cftr modulators such as symdeko/symkevi and tricaftor/kaftrio on pert usage and dios incidence in cf registry data post 2018. this will form the basis of future studies.

Eligibility criteria:
inclusion criteria: * all patients with cf of any genotype on the uk and us cystic fibrosis registries from the period 2007 - 2018. exclusion criteria: - patients whose cftr modulator status is unknown or only have one year of cftr data recorded on the registry will be excluded from the analysis of the effects of cftr modulators. this is to account for the fact that dios data is annualised on the registries, therefore there is no certainty at what time of year dios was diagnosed in relation to commencing cftr modulator therapy.

Keywords: cystic fibrosis distal intestinal obstruction syndrome pancreatic enzyme replacement therapy gastrointestinal symptoms gut symptoms
predicting postoperative pulmonary infection in elderly patients undergoing major surgery: a study based on logistic regression and machine learning models

Conditions: Postoperative Pulmonary Infection in Elderly Patients

Summary: although a number of clinical predictive models were developed to predict postoperative pulmonary infection, few predictive models have been used in elderly patients. in this study, the researchers aim to compare different algorithms to predict postoperative pulmonary infection in elderly patients and to assess the risk of postoperative pulmonary infection in elderly patients.


Eligibility criteria:
inclusion criteria: 1. age ≥ 65 years 2. patients who were mechanically ventilated under major surgery exclusion criteria: 1. preoperative tracheal intubation 2. preoperative pneumonia 3. organ transplantation 4. missing data
clinical trial of electro-acupuncture preconditioning in patients underwent heart valve replacement surgery

Conditions: Rheumatic Valve Disease

Summary: the purpose of this study is to investigate the protective effect of electro-acupuncture preconditioning in patients underwent cardiac surgery.

heart valve replacement surgery has been proved to be an effective method in treating both regenerative and rheumatic valve disease. current studies showed that cardiopulmonary bypass (cpb) and operation related myocardial injury, as indicated by the release of perioperative cardiac enzymes, is associated with worse patient morbidity and mortality after elective valve replacement surgery. although the actual mechanism is still unclear, it has been shown that ischemic preconditioning is one potential strategy for reduction of myocardial injury in open heart surgery. recently, electro- acupuncture (ea) was proved to produced cerebral protective and antiarrhythmic effects by mimicking ischemic preconditioning. this study aims to assess whether electroacupuncture preconditioning is also effective in reducing myocardial injury in adults with acquired heart valve disease undergoing elective valve replacement surgery.

Eligibility criteria:
inclusion criteria: * patients who have the indication for aortic or mitral valve replacement * patients would like to accept the follow-up and sign the informed consent * patients with heart function of nyha i-iii degree. exclusion criteria: * pregnant or nursing women * comorbid with coronary artery disease * patients with heart function of nyha iv degree * renal dysfunction with serum creatinine level\>or=2mg/dl(177umol/l) * anticipated life span \< 12 months * enrollment in other clinical trials at the same time not reaching the primary endpoint and probably interference the present trial.

Keywords: myocardial protection cardiac surgery heart valve replacement